CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 122 enrolled
Drug / intervention
Daptomycin 4 mg/kg +2 moredrug
Likely dose
Daptomycin 4 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00770341
NCT00770341Phase 3Completed
CompareCT.gov

A Phase III Randomized, Open-labeled Clinical Trial of MK-3009 (Daptomycin) in Patients With Skin and Soft Tissue Infections, Septicemia and Right-sided Infective Endocarditis Caused by MRSA

Merck Sharp & Dohme LLC·interventional·Posted Oct 10, 2008·Updated Mar 24, 2017

In Brief

A Phase 3 clinical trial evaluating Daptomycin 4 mg/kg, Comparator: vancomycin, and 1 other intervention for Staphylococcal Infection. Completed, enrolled 122 participants.

Detailed Summary

The study investigates the efficacy and safety of MK-3009 in participants with skin infections, septicemia and right-sided infective endocarditis (RIE) caused by methicillin-resistant Staphylococcus aureus (MRSA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStaphylococcal Infection
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 10, 2008
Enrollment StartSep 1, 2008
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.7 years ago

Interventions

Daptomycin 4 mg/kgdrug

MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)

Comparator: vancomycindrug

vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days

Daptomycin 6 mg/kgdrug

MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis